CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today celebrated the grand opening of the company’s new North American headquarters in Cambridge, Mass. As part of the festivities, more than 115 Ipsen employees took to the community for a Day of Service, supporting and volunteering for nine local charities and non-profit organizations.
“At Ipsen, our dedicated employees strive every day to help improve the lives of the patients we serve. We’re honored and thankful for their commitment to making a difference, and to having a positive impact on the communities in which we live and work,” said Richard Paulson, CEO of Ipsen North America. “Today is about more than marking the opening of our new Kendall Square headquarters – it’s about teamwork and giving back, and we’re proud to be here to participate.”
Ipsen’s Day of Service was coordinated with the help of Life Science Cares, an organization dedicated to eliminating poverty in the greater Boston area. Activities ranged from making updates and repairs to old buildings to cooking meals for families in need, and sorting and packaging clothing donations to prepare them for distribution. Participating organizations included:
- Boston Healthcare for the Homeless Program (BHCHP)
- Cambridge and Somerville Programs for Addiction Recovery (CASPAR)
- Cradles to Crayons Brighton
- Dimock Center Roxbury
- VA Boston Fisher House
- Breakthrough Greater Boston
- Message of Hope Foundation
- More Than Words Waltham
- Year Up Greater Boston
Ipsen announced the relocation of its North American headquarters from Basking Ridge, NJ to Cambridge in June 2018. With the move, the company co-located its Commercial business with its Research & Development, Manufacturing, and Global External Innovation and Partnering teams already based in Kendall Square – creating a fully integrated biopharmaceutical business in the United States. There are currently more than 290 employees in Kendall Square, with continued growth planned with the addition of more than 50 roles in 2019.
“This strategic move allows Ipsen to further capitalize on – and, importantly, invest in – the area’s robust biotech ecosystem to support our company’s accelerated growth, as well as leverage key industry partnerships and major academic prowess in the area,” added Paulson. “It also provides access to top talent, and an opportunity to raise our profile and visibility as an employer of choice.”
Today’s grand opening includes celebration of Ipsen’s new 50,000-square-foot headquarters at One Main Street and the company’s recently renovated 46,000-square-foot facility at 650 East Kendall Street, home of Ipsen’s R&D and Global External Innovation and Partnering teams, as well as the Ipsen Innovation Center – Biolabs, a 15,000-square-foot life science co-working facility dedicated to supporting entrepreneurs and startup companies developing the next generation of therapeutics for patients. Ipsen also has a manufacturing facility located at One Kendall Square.
ABOUT IPSEN IN NORTH AMERICA
Ipsen (Euronext: IPN; ADR: IPSEY) is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen’s North American operations are located in Cambridge, Massachusetts, one of the company’s three global hubs. Based in the heart of Kendall Square, our fully integrated biopharmaceutical business includes Commercial, Research & Development, Manufacturing, and Global External Innovation and Partnering. Combined with our Canadian headquarters in Mississauga, Ontario, and other locations, Ipsen employs approximately 600 people in North America. For more information please visit www.ipsenus.com or www.ipsen.ca. Connect with us on Twitter and LinkedIn.